Biotechnology News

Second quarter 2018 revenue increased 53% to $3.4 million, compared with $2.2 million in same period in 2017The Company estimates total revenues for 2018 to reach $13 -14 million, an increase of 37 –...

Company Announcement DARZALEX approved in Europe in combination with bortezomib, melphalan and prednisone in patients with newly diagnosed multiple myelomaApproval follows positive...

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments...

Studies funded by BARDA GAITHERSBURG, Md., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced initial data from its Phase...

CAMBRIDGE, Mass., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies,...

WATERTOWN, Mass., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...

SALT LAKE CITY, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president...

CRANBURY, N.J., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at two investor conferences in September. Bradley Campbell, President and...

­­31 August 2018 Midatech Pharma PLC("Midatech" or the "Company") Midatech Announces Interim Results from Proof of Concept Exploratory Study for its MTD201 Q-Octreotide Programme and Q-Sphera™...

BEIJING, China, and CAMBRIDGE, Mass., Aug. 31, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...